CA2285350A1 - Traitement de la fibrose pulmonaire - Google Patents

Traitement de la fibrose pulmonaire Download PDF

Info

Publication number
CA2285350A1
CA2285350A1 CA002285350A CA2285350A CA2285350A1 CA 2285350 A1 CA2285350 A1 CA 2285350A1 CA 002285350 A CA002285350 A CA 002285350A CA 2285350 A CA2285350 A CA 2285350A CA 2285350 A1 CA2285350 A1 CA 2285350A1
Authority
CA
Canada
Prior art keywords
halofuginone
group
pulmonary fibrosis
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002285350A
Other languages
English (en)
Inventor
Mark Pines
Arnon Nagler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2285350A1 publication Critical patent/CA2285350A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition permettant de traiter la fibrose pulmonaire, ainsi qu'une méthode permettant d'utiliser et de fabriquer ladite composition. Cette dernière contient un dérivé de la quinazolinone, de préférence l'halofuginone. La voie d'administration préférée est l'inhalation, de préférence avec un support pharmaceutiquement acceptable se présentant sous forme d'aérosol.
CA002285350A 1997-03-31 1997-03-31 Traitement de la fibrose pulmonaire Abandoned CA2285350A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL1997/000115 WO1998043642A1 (fr) 1997-03-31 1997-03-31 Traitement de la fibrose pulmonaire

Publications (1)

Publication Number Publication Date
CA2285350A1 true CA2285350A1 (fr) 1998-10-08

Family

ID=11061990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002285350A Abandoned CA2285350A1 (fr) 1997-03-31 1997-03-31 Traitement de la fibrose pulmonaire

Country Status (5)

Country Link
EP (1) EP0991411A4 (fr)
JP (1) JP2001518062A (fr)
AU (1) AU737094B2 (fr)
CA (1) CA2285350A1 (fr)
WO (1) WO1998043642A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0944382A1 (fr) 1996-09-30 1999-09-29 Brigham & Women's Hospital Methodes et composes destines au traitement de l'hemorragie uterine anormale
WO2001017531A1 (fr) * 1999-09-09 2001-03-15 Hadasit Medical Research Services And Development Company Ltd. Promotion de cicatrisation de blessures
WO2008087650A2 (fr) * 2007-01-21 2008-07-24 Agricultural Research Organization Composition et procédé pour traiter ou prévenir une fibrose des muscles squelettiques
AU2013270622B2 (en) * 2007-01-21 2016-05-19 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2019237125A1 (fr) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibiteurs de la prolyl-arnt-synthétase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113229C (fr) * 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
EP0991411A1 (fr) 2000-04-12
WO1998043642A1 (fr) 1998-10-08
AU737094B2 (en) 2001-08-09
JP2001518062A (ja) 2001-10-09
EP0991411A4 (fr) 2000-05-31
AU2042097A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
US6313131B1 (en) Method of kidney treatment
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
ES2311973T3 (es) Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica.
CN112166111A (zh) 治疗纤维化疾病的方法
US20210069192A1 (en) Use of neutrophil elastase inhibitors in liver disease
CA2568436A1 (fr) Therapie combinee impliquant un antagoniste de recepteur d'adenosine a1 et un inhibiteur d'aldosterone
AU737094B2 (en) Treatment for pulmonary fibrosis
JP2002534477A (ja) メラガトランの新規使用
JP2006518765A (ja) アデノシンａ１受容体アンタゴニストを使って疾患を処置する方法
AU2002350832B2 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
MX2010014223A (es) Composiciones pediatricas para el tratamiento de esclerosis multiple.
US6562829B1 (en) Treatment of hepatic cirrhosis
CA2120319C (fr) Compose pharmaceutique pour le traitement des dermatopathies
JP2003522121A (ja) 多発性硬化症の処置のためのリルゾールの使用
MX2008012729A (es) Inhibidores de renina para el tratamiento de hipertension.
EP1333855A1 (fr) Utilisation de melagatran pour la production d'un medicament destine au traitement de troubles ischemiques
AU2001225625A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
US7612082B2 (en) Prostaglandin EP4 antagonists
JPH07196509A (ja) イソキノリン誘導体を含有する医薬組成物
KR101293350B1 (ko) 호중구증다 억제제
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
KR100540537B1 (ko) 간경변의 치료방법
AU2008257319B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
JPS6058726B2 (ja) プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead